



European Reference Network: Clinical Practice Guidelines And Clinical Decision Support Tools

September 28th 2020

Methodological Handbooks &
Toolkit for Clinical Practice Guidelines
and Clinical Decision Support Tools for Rare
or Low-Prevalence and Complex Diseases

Handbook #5: Methodology for the Development of Clinical Consensus Statements for Rare or Low-Prevalence and Complex Diseases

Prepared by:
Aragon Health Sciences Institute (IACS)

LEGAL NOTICE

This report was produced under the third Health Programme (2014–2020). The content of this report represents the views of the contractor and is its sole responsibility; it can in no way be taken to reflect the views of the European Commission or any other body of the European Union. The European Commission do not guarantee the accuracy of the data included in this report, nor do they accept responsibility for any use made by third parties thereof.

More information on the European Union and on European Reference Networks is available on the Internet (<http://www.europa.eu>) (https://ec.europa.eu/health/ern_en)

© European Union, 2020

Reproduction is authorised provided the source is acknowledged.

EUROPEAN COMMISSION

Directorate-General for Health and Food Safety

Directorate B — Health systems, medical products and innovation

Unit B.3 — Digital Health, European Reference Networks

Contact: Enrique Terol

E-mail: enrique.terol@ec.europa.eu

European Commission B-1049 Brussels



Authors:

Lucía Prieto Remón, BA in Business and Marketing

Aragon Health Sciences Institute (IACS, Spain)

Patricia Gavín Benavent, MD, PhD

Aragon Health Sciences Institute (IACS, Spain)

Authors: Internal Reviewers (in alphabetical order)

María Bono Vega, BSc in Biochemistry

Aragon Health Sciences Institute (IACS, Spain)

María Soledad Isern de Val, BSc in Biochemistry, PhD

Aragon Health Sciences Institute (IACS, Spain)

Celia Muñoz Fernández, BA in Economics

Aragon Health Sciences Institute (IACS, Spain)

Authors: Collaborators

María Pilar Blas Díez, Information Specialist

Aragon Health Sciences Institute (IACS, Spain)

Contact Information:

FPS-AETSA

ERNGuideLinesCoordination.fps@juntadeandalucia.es

Fundación Pública Andaluza Progreso y Salud (FPS)

Avd. Américo Vespucio 15, Edificio S-2

C.P. 41092 Seville, Spain

+34 955 006636



This handbook includes a detailed explanation of the process for developing Clinical Consensus Statements for rare diseases, including:

- ✓ Consensus coordination team
- ✓ Recruitment of participants
- ✓ Clinical consensus method
- ✓ Development of the questions
- ✓ Edition of the consensus.

Purpose:

To provide guidance for the development of Clinical Consensus Statements for rare diseases.





TABLE OF CONTENTS

Background	7
1.1 Context for the development of Clinical Consensus Statements in rare diseases	7
1.2 The Clinical Consensus Statement development process: main steps	8
Consensus coordination team	9
2.1 Coordination team leader	9
Recruitment of participants (consensus panel)	10
3.1 Profiles	10
3.2 Recruitment	10
3.3 Management of conflicts of interest	11
Clinical Consensus Methods	12
4. 1 Formal Consensus	12
4.1.1 Delphi	12
4.1.2 Nominal Group Technique (NGT)	13
4.1.3 Consensus Development Conference (CDC)	14
4.2 Informal consensus	15
Development of the questions	17
5.1 Definition of the scope and purpose	17
5.2 Literature review	17
5.3 Selection of the type of questions	18
5.4 Formulation of questions	18
Edition of the Clinical Consensus Statement	19
Bibliography	20



ABBREVIATIONS

AETSA	Andalusian Health Technology Assessment Department
CDC	Consensus Development Conference
CDSTs	Clinical Decision Support Tools
CPGs	Clinical Practice Guidelines
DG	Development Group
EC	European Commission
ERN	European Reference Network
FPS	Fundación Progreso y Salud
GRADE	Grading of Recommendations Assessment, Development and Evaluation
HTA	Health technology assessment
IACS	Aragon Health Sciences Institute
NGT	Nominal Group Technique
SR	Systematic Reviews



01.

BACKGROUND

There are a number of challenges surrounding the development of CPGs and CDSTs for rare diseases. One of the most relevant barriers is the lack of high-quality evidence, which cutting-edge methodological frameworks like GRADE¹ rely on.

Therefore, there is a need for specific methodological approaches that can provide reliable and useful Clinical Practice Guidelines (CPGs) and Clinical Decision Support Tools (CDSTs) for rare diseases. The project also aims to provide a common methodology to harmonise the development of CDSTs and CPGs.

It is worth noting that within the scope of this document, “rare diseases” is the term used to refer to rare diseases as well as low prevalence complex diseases.

1.1 | Context for the development of Clinical Consensus Statements in rare diseases

Clinical consensus statements reflect opinions drafted by subject-matter experts for which consensus is sought using an explicit method to identify areas of agreement and disagreement. In contrast to clinical practice guidelines, which are based primarily on high-level evidence, clinical consensus statements are more applicable to situations in which evidence is limited or lacking, yet there are still opportunities to reduce uncertainty and improve quality of care^{2,3}. They offer specific recommendations on a topic. They do not provide specific algorithms or guidelines for practice.

Clinical consensus has different applications ranging from defining appropriateness of procedures to prioritisation of treatment options⁴.



1.2 | The Clinical Consensus Statement development process: main steps

TASK	DEFINITION
Consensus coordination team	<ul style="list-style-type: none">• Constitution of the team that will lead and oversee the development of the consensus process.
Recruitment of participants	<ul style="list-style-type: none">• Composition of the consensus panel (participants).
Clinical consensus method	<ul style="list-style-type: none">• Selection of the method the method that will be used to reach consensus
Development of the questions	<ul style="list-style-type: none">• Development of the questions that will be used to foster the initial discussions and develop the next ones.
Edition of the consensus	<ul style="list-style-type: none">• Edition of the document that describes the consensus process and its results, including the clinical consensus statements.



02.

CONSENSUS COORDINATION TEAM

The consensus coordination team is formed by 2-3 persons and the leader, who should have enough methodological expertise or at least include one methodologist. International expertise can be included in the panel. The main function of the coordination team is to lead and oversee the consensus process, which includes the following main tasks ²:

- ✓ Selection of the consensus method to be used.
- ✓ Preparation of the consensus process, including the configuration of the consensus panel (participants) and appointment of experts (only in CDC), development of the questions and questionnaires and definition of the consensus threshold.
- ✓ Act as main contact point for panellists and keep them informed.
- ✓ Facilitate the discussions and record the results during the discussions, when needed.
- ✓ Analysis and aggregation of results.
- ✓ Assist in the development of the final consensus statement.
- ✓ Edition of the consensus.

2.1 | Coordination team leader

She or he will lead the work of the coordination team and the consensus process and should have knowledge of the topic, experience regarding consensus methods².

One of the leader's tasks is usually to facilitate consensus discussions, although this function may be assumed by another member of the coordination team if necessary. The main objective of the facilitator is to ensure that the group makes the best quality decision possible. Nonetheless, the final decision is ultimately the group's responsibility. Other primary responsibilities as facilitator are the following ²:

- ✓ Seek equal participation of all members during discussions
- ✓ Encourage constructive debate
- ✓ Keep deliberation and input within the scope of the consensus



03.

RECRUITMENT OF PARTICIPANTS (CONSENSUS PANEL)

3.1 | Profiles

The participants should be experts on the subjects relevant to the topic and question(s) that the consensus addresses integrating the set of activities of all the professionals involved^{5,6,7}. The following profiles should be considered:

- ✓ Care professionals relevant to the topic of the consensus, including healthcare, social care and other professionals. For diseases revealed at paediatric age, the group should include specialists in childhood and adulthood management of the disease in order to cover the transition from paediatric to adult healthcare services⁸.
- ✓ Healthcare Managers relevant to the topic of the consensus.
- ✓ Patients and carers.

When the term 'patients and carers' is used in this handbook, it is intended to include people with specific rare disease conditions and disabilities and their family members and carers. It also includes members of organisations representing the interests of patients and carers.

Other profiles may be considered if deemed relevant to the topic. If the topic is derived from a CPG or CDST, members from the development group have been involved in the development of the clinical consensus statements⁵.

3.2 | Recruitment

There are some issues that should be considered when planning and conducting the recruitment of participants, in addition to those already indicated in the description of each method earlier in this handbook²:

- ✓ They represent their fields of expertise, enriched with their personal insight, knowledge and experience, not the organisation(s) they may be affiliated to. This should be explained and clarified with them during recruitment.
- ✓ They should be available to commit to participating in all the steps or phases of the consensus process, e.g. conferences, questionnaires or meetings.
- ✓ Higher-status participants are likely to exert more influence in the group⁹.

- ✓ Homogeneous groups are appropriate if the aim is to define common ground and maximise areas of agreement, but risk giving rise to polarized judgements due to polarized homogeneous views ⁴.
- ✓ Heterogeneous groups are suitable if the aim is to identify and explore areas of uncertainty, but risk not reaching a consensus ¹⁰.

3.3 | Management of conflicts of interest

Potential conflict of interests among the participants should be carefully identified and duly addressed, following the indications established by our partner FPS.



04.

CLINICAL CONSENSUS METHODS

4.1 | Formal Consensus

Formal consensus methods are structured processes with specific formal requirements. Certain reasons motivate the use of formal consensus methods ¹¹:

- ✓ Control of the process: by providing a structured process, formal methods can contribute to eliminating negative aspects of group decision-making, e.g. avoiding group decisions being dominated by the opinion of one or a few members.
- ✓ Scientific credibility: formal consensus methods meet the requirements of scientific methods.

The three primary formal consensus methods are addressed in this handbook ¹⁰: Delphi, Nominal Group Technique (NGT) and Consensus Development Conference (CDC).

These methods can be combined or modified and used in a two-step process, e.g. using one method as an initial approach to the consensus and the other method to reach final consensus ⁷.

4.1.1 | Delphi

Delphi is an iterative technique based on successive rounds of questionnaires that aims to reduce the range of responses and help the group to arrive at something closer to expert consensus ¹².

Delphi is more appropriate when the number of experts is high and/ or it is difficult to meet face-to-face for logistical or economic reasons, e.g. when the consensus panel (participants) are geographically dispersed ¹³.



Delphi process	
Preparation of the Delphi	<ul style="list-style-type: none">• Definition of the question or questions that will be addressed in Delphi ¹⁴, e.g. development of a set of diagnostic/classification criteria (see section 5).• Recruitment/invitation to the selected participants, providing clear information on the process and the purpose of Delphi. The participants in Delphi can be very numerous (even hundreds), but should include at least 10-30 panellists (see section 3).• Definition of the level of consensus, i.e. the threshold that will determine that consensus has been reached over a given issue.
First round	<p>The participants are asked to answer to the initial questionnaire, where they are also invited to provide additional information or suggest new items or modifications to the proposed ones, based on their opinions or experience. The results of the first round are analysed by the coordination team with simple descriptive statistics and summarized to generate a series of statements.</p> <p>Consensus may have been reached on some issues. The issues on which there is still no agreement are used to build the questionnaire that will be used in the second round.</p>
Second round	<p>The second questionnaire is sent to the participants, together with feedback from the first round, i.e. the overall results and his/her own previous reply/scores. Participants are then given the opportunity to reconsider their respective previous opinions and adjust the answer, e.g. by re-rating the level of agreement.</p> <p>The results of the second round are analysed and if there are still issues upon which no consensus has been reached, a third round will be done, repeating the process of the second round.</p> <p>Two to four rounds are usually necessary to develop the final consensus⁷.</p>
Development of the final consensus statement	<p>A report on the development of the Delphi rounds is developed by the coordination team. In it, the results of each round are indicated, together with the final set of statements and level of agreement reached on them. This report is reviewed by the participants to ensure it reflects the views they shared during the consensus process. After this review, the final consensus document is produced.</p>

4.1.2 | Nominal Group Technique (NGT)

The nominal group technique (NGT) is a structured interaction based on silently and individually generated ideas that are discussed and ranked in a group session in which all the consensus panel (participants) voice their opinions.





NGT process	
Preparation of the NGT	<ul style="list-style-type: none"> • Definition of the question or questions that will be addressed in the NGT, e.g. development of a set of diagnostic/classification criteria (see section 5). • Recruitment/invitation to the selected participants, providing clear information on the process and the purpose of the NGT. The group of participants should include 5–9 experts. Larger groups can be separated into different groups of 5–9 participants, which will work simultaneously on the same questions ¹⁵. If several groups are formed, representativeness of profiles should be maintained in all of them (see section 2). • Definition of the level of consensus, i.e. the threshold that will determine that consensus has been reached over a given issue. Generally 70– 80% consensus is required ¹⁶, although a lower threshold could be defined ¹⁷.
Phase 1	The participants are asked to record privately and independently on a piece of paper ideas to address the question(s), for 5-10 minutes.
Phase 2	One idea is collected from each individual in turn and listed in front of the group by the facilitator, continuing until all ideas have been listed. No discussion is conducted at this time.
Phase 3	A brief discussion on each idea is led by the facilitator with the aim of clarifying the ideas or statements ¹⁵ .
Phase 4	After the discussions, the participants privately record their judgements or assign scores to the ideas and share them with the rest of the group in turn.
Final phase	Finally, the individual judgements or votes are aggregated statistically to derive the group judgement which will define the statement or statements. Each idea is privately ranked or rated on a scale of 1–5 or 1–10. The highest ranking solutions will be kept while the remaining solutions are discarded.

4.1.3 | Consensus Development Conference (CDC)

CDC is a semi-public process where consensus panel (participants) receive information from experts and interest groups and reach consensus after several rounds of discussion.

CDCs are frequently used to agree on the safety, efficacy and/or appropriateness of using various medical procedures, drugs, and devices ¹⁸ that arouse public interest. It is an appropriate method when the subject in question is of social relevance and/or entails certain controversy that transcends the professional field.





CDC Process	
Preparation of the CDC	<ul style="list-style-type: none"> • Definition of the question or questions that will be addressed in the CDC, e.g. the appropriateness of the use of a certain treatment for a given population (see section 5). • Recruitment/ invitation to the selected participants, providing clear information on the process and the purpose of the CDC. The CDC panel should have around 10 experts. The participants should be independent individuals highly regarded in their field of expertise but not closely aligned with the subject ⁷ (see section 3). • Appointment and invitation to the experts and other stakeholders who will present the evidence to the participants of the CDC. In the case of stakeholders, representativeness should be carefully regarded and patients and carers should be invited. • Definition of the level of consensus, i.e. the threshold that will determine that consensus has been reached over a given issue.
Presentation of the questions	The questions are publicly presented and explained to the CDC in the conference.
Presentation of the evidence	<p>The experts and stakeholders appointed present the evidence to the CDC participants. The timing should be established in advance, including time for Questions & Answers and discussion. The facilitator will oversee the presentations, Q&A and discussions, making sure that the pre-defined times are respected.</p> <p>The general public attending the conference is also welcomed to comment on the presentations during the Q&A and ask questions to the experts and stakeholders and also to the participants.</p>
Private deliberation	After the presentations and the discussions, the participants of the CDC meet in a private session to further deliberate and reach a consensus, weighting the information received during the presentation of the evidence.
Presentation of consensus statement draft	The consensus statement is presented as a draft in a public session. The general public is invited to review and comment on it.
Development and dissemination of final consensus statement	<p>The CDC participants meet in a private meeting where the draft consensus statement may be modified following the comments and suggestions received during the last presentation.</p> <p>The final consensus statement is made public and disseminated widely to achieve maximum impact on health care practice and medical research⁷.</p>

4.2 | Informal consensus

Informal consensus is the process in which a group of individuals come to agree on a choice or choices without following any formal decision-making of any kind. Despite the lack of formal structure or methodology, the general steps and considerations described in this handbook should be followed in order to ensure the consensus is relevant and valid.

As regards the number of members of the consensus panel (participants), if there are more





participants, the reliability of the statements is presumed to be higher ¹⁴. As a minimum, there should be six participants ^{19,4}. Nonetheless, a number higher than twelve may be more difficult to coordinate ¹⁴.



05.

DEVELOPMENT OF THE QUESTIONS

In order to develop the questions, the following steps should be followed:

5.1 | Definition of the scope and purpose

Covering:

- ✓ Target population: The characteristics of the population(s) of interest and any respective subgroups on which the consensus will focus, including the age, type of disease or condition, severity or comorbidities.
- ✓ Aspects to be covered: Care aspects that will be addressed in the consensus, e.g., effectiveness, safety, appropriateness.

5.2 | Literature review

A literature review should be conducted to define the questions or preliminary set of items or statements. More information on the search of scientific evidence can be found in Handbook #4: Methodology for the Development of CPGs for Rare Diseases.

Sources of information:

The sources of evidence should be considered in the following order: 1) CPGs and CDSTs; 2) Systematic Reviews (SR); 3) Health Technology Assessment (HTA) reports; 4) Original studies.

It is likely that there will be no Systematic Reviews (SRs) and/or CPGs or CDSTs on the specific topic of the consensus, but those with a broader scope that includes the specific topic of the consensus should be considered, as they may assist in identifying specific areas of ambiguity or variations in practice. For example, a review or guideline on the broad topic of “sinusitis” may nonetheless have useful information on the narrower topic of “paediatric chronic sinusitis.”²

More information on the search of the evidence can be found in Handbook #4: Methodology for the Development of CPGs for Rare Diseases.

Synthesis of the evidence:

A synthesis of the evidence should be developed and delivered to the participants before the consensus process starts. More information on the synthesis of the evidence can be found in Handbook #4: Methodology for the Development of CPGs for Rare Diseases.



5.3 | Selection of the type of questions

- ✓ If the consensus aims to develop a list of prioritised criteria, the questions will ask about the priority (e.g. relevance, appropriateness, etc.) of a set of items or statements ¹⁰.
- ✓ If the consensus aims at developing recommendations, two type of questions can be used:
 - Technical questions, where judgement is needed because of insufficient data.
 - Value questions, where judgement is needed about competing social goals.

There can be no 'correct' answer for value questions, whereas for technical questions, there is a correct, if undiscovered, answer.

5.4 | Formulation of questions

The questions should be clearly and concisely stated. In the case of Delphi questionnaires, the response elicited should be in a simple and straightforward fashion, e.g. the questions would require a yes/no answer or details of the level of agreement or disagreement (by means of a Likert scale) with each item.

Ideally, participants should be given the opportunity to comment on the questions presented, correct them and/or add new ones. This should be done in the first phase of the consensus process ⁴.

Key issues

- The consensus coordination team leads and oversees the consensus process, from the selection of the method to the edition of the consensus. The leader of the team gathers technical and methodological expertise and frequently acts as facilitator in the discussions.
- When planning the recruitment of the consensus participants, their profile, the capacity in which they participate, their commitment to finalising the process, the homogeneity and heterogeneity of the group and potential conflicts of interests should be considered.
- Formal consensus offers a structured methodology, whereas informal consensus provides a more flexible approach to reaching agreements. The appropriateness of each method may depend on the nature of the topic and the number of participants. Different methods may be combined.
- The scope and purpose of the consensus covers the target population addressed in the consensus and the aspects covered. The literature review to inform the development of the questions and the synthesis that will be shared with the participants should comprise CPGs, CDSTs, SRs, HTA reports and original studies.



06.

EDITION OF THE CLINICAL CONSENSUS STATEMENT

The consensus process and results should be documented and edited with the following information:

- ✓ Rationale for using consensus method, including explicit and well-founded justification of the lack of the scientific evidence to formulate evidence-based recommendations.
- ✓ Consensus method used and rationale for choosing it.
- ✓ Consensus panel, including the number of participants, profile, name, expertise, institution and geographical location.
- ✓ Coordination team, including the number, profile, name, expertise, institution and geographical location.
- ✓ Process for the development of questions, including the questionnaires and other material delivered to the consensus participants.
- ✓ Literature review conducted and its results.
- ✓ Results of the consensus process at each step, including turnout. Significant dropouts should be analysed and substantiated.
- ✓ Consensus statement(s), linked to the level of consensus reached at each statement.



07.

BIBLIOGRAPHY

1. Guyatt G, Oxman AD, Akl EA, Kunz R, Vist G, Brozek J, et al. GRADE guidelines: 1. Introduction- GRADE evidence profiles and summary of findings tables. *Journal of clinical epidemiology*. 2011;64(4):383-94.
2. Rosenfeld RM, Nnacheta LC, Corrigan MD. Clinical Consensus Statement Development Manual. *Otolaryngology-head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery*. 2015;153(2 Suppl):S1-S14.
3. Beighton D. Consensus Statements. *Caries research*. 2017;51(5):I-II.
4. Kea B, Sun BCA. Consensus development for healthcare professionals. *Internal and emergency medicine*. 2015;10(3), 373-383.
5. Kwong JS, Chen H, Sun X. Development of Evidence-based Recommendations: Implications for Preparing Expert Consensus Statements. *Chinese Medical Journal*. 2016;129(24):2998-3000.
6. Decamp M, Joffe S, Fernandez CV, Faden RR, Unguru Y. Chemotherapy drug shortages in pediatric oncology: a consensus statement. *Pediatrics*. 2014;133(3):e716-24.
7. Nair R, Aggarwal R, Khanna D. Methods of formal consensus in classification/diagnostic criteria and guideline development. *Semin Arthritis Rheum*. 2011;41(2):95-105.
8. Haute Autorité de Santé (HAS). Méthode d'élaboration d'un protocole national de diagnostic et de soins pour les maladies rares: Guide Methodologique [Internet]. 2012 [cited 15/06/2020]. Available from : https://www.has-sante.fr/jcms/c_1342513/fr/guide-methodologique-pnds
9. Vinokur A, Burnstein E, Sechrest L, Wortman PM. Group decision making by experts: field study of panels evaluating medical technologies. *Journal of Personality and Social Psychology*. 1985; 49:70-84.
10. Black N, Murphy M, Lamping D, et al. Consensus development methods: a review of best practice in creating clinical guidelines. *J Health Serv Res Policy*. 1999;4(4):236-248.
11. Janis I. Groupthink. In E. Griffin (ed.) *A First Look at Communication Theory*. New York: McGrawHill; 1991. p. 235-246.
12. RAND Corporation [Internet]. [cited 15/06/2020]. Delphi Method. Available from: <https://www.rand.org/topics/delphi-method.html>
13. Delbecq AL, Van de Ven AH, Gustafson DH. Group techniques for program planning: A guide



to nominal group and delphi processes. Middleton, WI: Green Briar Press; 1975.

14. Murphy MK, Black NA, Lamping DL, McKee CM, Sanderson CF, Askham J, et al. Consensus development methods, and their use in clinical guideline development. *Health Technology Assess.* 1998;2: 1–88.
15. Ruperto N, Meiorin S, Iusan SM, Ravelli A, Pistorio A, Martini A. Consensus procedures and their role in pediatric rheumatology. *Curr Rheumatol Rep.* 2008;10(2):142–146.
16. Giannini EH, Ruperto N, Ravelli A, Lovell DJ, Felson DT, Martini A. Preliminary definition of improvement in juvenile arthritis. *Arthritis Rheum.* 1997;40(7):1202–1209.
17. Khanna D, Lovell DJ, Giannini E, Clements PJ, Merkel PA, Seibold JR, et al. Development of a provisional core set of response measures for clinical trials of systemic sclerosis. *Ann Rheum Dis.* 2008 ;67(5):703–709.
18. Fink A, Kosecoff J, Chassin M, Brook RH. Consensus methods: characteristics and guidelines for use. *Am J Public Health.* 1984;74(9):979-983.
19. Hogarth R. A note on aggregating opinions. *Organizational Behavior and Human Performance.* 1978; 21:40–46.



European
Reference
Networks



European
Reference
Networks

ERN
GUIDELINES